Do you want to read an article? Please log in or register.
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
Lung Cancer
Related content
Lung Cancer
Efficacy and Safety of EGFR-TKI Combined With Early Brain Radiotherapy Versus TKI Alone in Patients With EGFR-Mutated NSCLC With Brain Metastases: A Systematic Review and Meta-Analysis
Clin Lung Cancer
Zeng Z, Feng S, Gao T, Chen C, Chen J, Chen J, Lian Y
doi: 10.1016/j.cllc.2025.04.010
Lung Cancer
Central Nervous System Outcomes of Lazertinib Treatment in EGFR-Mutated Advanced NSCLC: Pooled Analysis From LASER201 and LASER301
Clin Lung Cancer
Yang JC, Ahn MJ, Kim JH, Lee YG, Han JY, Lee KH, Zimina A, Kim DW, Lee KH, Lee SS, Lim CS, Lim YN, Min YJ, Orlov S, Lee Y, Kim Y, Kwon MJ, Lee H, Cho H, Cho BC
doi: 10.1016/j.cllc.2025.08.007
Lung Cancer
Impact of TP53 Co-Mutation on Clinicopathological Features, Prognosis, Recurrence Patterns, and the Efficacy of EGFR-TKI Treatment After Recurrence in Resected Early-Stage EGFR-Mutated Lung Adenocarcinoma
Clin Lung Cancer
Masuda T, Katsumata S, Isaka M, Serizawa M, Kawata T, Asami M, Yamaguchi D, Matsushima K, Hayasaka K, Kojima H, Yokomakura N, Konno H, Nagashima T, Urakami K, Yamaguchi K, Ohde Y
doi: 10.1016/j.cllc.2025.04.009
Lung Cancer
LAURA Completes the Osimertinib Treatment Jigsaw Puzzle of EGFR+ NSCLC from Stage IB to IV: Adjuvant Osimertinib Significantly Improves PFS and CNS Progression in Unresectable Stage III EGFR-Mutated NSCLC Compared to Placebo (LAURA, NCT03521154)
Lung Cancer (Auckl)
Luo FX, Arter Z, Ou SI, Nagasaka M
doi: 10.2147/LCTT.S520833
Lung Cancer
Elucidating the Role of EGFR(L858R) in Brain Metastasis Among Patients With Advanced NSCLC Undergoing TKI Therapy
Clin Lung Cancer
Rios-Garcia E, Guijosa A, Caballé-Perez E, Davila-Dupont D, Izquierdo C, Regino A, Lozano-Vazquez N, Solis A, Lara-Mejía L, Remon J, Cacho-Díaz B, Cardona AF, Arrieta O
doi: 10.1016/j.cllc.2025.01.004
Lung Cancer
Stratifying risk in oligoprogressive EGFR-mutated non-small cell lung cancer (NSCLC): The role of liquid biopsy
Lung Cancer
Guijosa A, Rios-Garcia E, Dávila-Dupont D, Cruz-Rico G, Russo A, Cabrera Miranda LA, Cardona AF, Rolfo C, Arrieta O
doi: 10.1016/j.lungcan.2025.108722
RECOMMENDED
Lung Cancer
Real-world survival outcomes of immune checkpoint inhibitor therapy after standard treatment failure in EGFR-mutated NSCLC: A nationwide cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Lee J, Kim M, Han HJ, Kim S, Suh HS
doi: 10.1016/j.lungcan.2025.108682
Lung Cancer
Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial
Lancet Respir Med
Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, Yang R, Miao L, Zhang G, Gao H, Sun L, Zhang M, Cang S, Sun M, Yao W, Pan Z, Cui J, Xiao Y, Wang Q, NCT04143607 Study Group
doi: 10.1016/S2213-2600(25)00121-3
Lung Cancer
Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study
Lancet Respir Med
Shi Y, Guo Y, Li X, Wu L, Chen Z, Yang S, Bi M, Zhao Y, Yao W, Yu H, Wang K, Zhao W, Sun M, Zhang L, He Z, Lin Y, Shi J, Zhu B, Wang L, Pan Y, Shi H, Sun S, Wen M, Zhou R, Guo S, Han Z, Yi T, Zhang H, Cang S, Yu Z, Zhong D, Cui J, Fang J, Gao J, Li M, Ma R, Jiang M, Qin J, Shu Y, Ye F, Hu S, Li W, Lu H, Yang M, Yi S, Zhang Y, Fan Y, Ji H, Liu Z, Wang H, Zhou X, Zhang D, Peng J, Shen H, Gao F, Wang T, Zhou A
doi: 10.1016/S2213-2600(24)00417-X